Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Thalidomide treatment proves better than conventional chemotherapy for multiple myeloma


When people hear "thalidomide," many think "birth defects," however, evidence has come to light that this once-banned drug can be used as a potent anti-cancer treatment. In a new study, researchers from the University of Bologna, Italy, demonstrate that Thal-Dex (thalidomide used in combination with dexamethasone) is more powerful than conventional chemotherapy for the treatment of multiple myeloma. Their findings will be published in the July 1, 2005, issue of Blood, the official journal of the American Society of Hematology.
Each year, approximately 15,000 Americans are diagnosed with multiple myeloma, an incurable and painful disease of the bone marrow. Most patients who receive this diagnosis have less than five years to live; however, many can undergo autologous (self-donor) stem cell transplants to help prolong survival. Although thalidomide has been studied for the treatment of advanced stages of multiple myeloma since the late 1990s, this is the first large study to compare its effectiveness to standard drugs as part of front-line therapy with stem cell transplantation.

Because the odds for a successful transplant increase as the number of cancer cells decreases, patients receive chemotherapy a few months before the procedure. In this study, 100 multiple myeloma patients given Thal-Dex before transplant were compared to 100 patients given traditional chemotherapy with VAD (a combination of three drugs: vincristine, adriamycin, and dexamethasone).

Thal-Dex patients were more likely to have successful results; 76 percent received at least a partial remission. Of the VAD patients, only 52 percent had a positive response to treatment, meaning that nearly half had either no response, or a progression of their disease. Patients taking Thal-Dex also had a more profound reduction in the size of their tumors.

Not only was Thal-Dex a more effective treatment, but its two-pill regimen is also greatly preferred by patients over intravenous VAD treatments. A vital consideration for patients undergoing autologous stem cell transplant is that toxicity from chemotherapy not impair the collection of stem cells needed for the transplant. In that respect, patients in both the Thal-Dex and the VAD group were able to collect enough healthy stem cells for transplantation and there was no significant difference between the two.

main side effect of Thal-Dex was deep vein thrombosis, which 15 percent of patients on the drug experienced. Although this effect was treated successfully with anti-coagulants, researchers speculate that further research needs to be done to help predict which patients will experience this outcome in order to find ways to make treatment with Thal-Dex safer for them. The main side effect of VAD was granulocytopenia (low white blood cell levels), which was severe in 12 percent of the patients in that group.

"It’s time to look at thalidomide in a new light," said Michele Cavo, M.D., professor at the University of Bologna and lead study author. "It’s earned its place in modern medicine. Thalidomide has proven to be a highly effective, relatively safe, and more comfortable treatment for patients with multiple myeloma than traditional chemotherapy."

This work was supported by grants from the University of Bologna, the Ministero dell’Università e Ricerca Scientifica, and the Carisbo Foundation.

Laura Stark | EurekAlert!
Further information:

More articles from Studies and Analyses:

nachricht Diagnoses: When Are Several Opinions Better Than One?
19.07.2016 | Max-Planck-Institut für Bildungsforschung

nachricht High in calories and low in nutrients when adolescents share pictures of food online
07.04.2016 | University of Gothenburg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Oasis of life in the ice-covered central Arctic

24.10.2016 | Earth Sciences

‘Farming’ bacteria to boost growth in the oceans

24.10.2016 | Life Sciences

Light-driven atomic rotations excite magnetic waves

24.10.2016 | Physics and Astronomy

More VideoLinks >>>